Companies that own Evotec AG
DWS Investment GmbH
8,831,914
5.98%
-73,892
0.13%
08/31/2018
Allianz Global Investors GmbH
7,222,659
4.88%
-143,619
0.22%
08/10/2018
Norges Bank Investment Management
3,700,512
2.5%
1,328,755
0.01%
12/31/2017
The Vanguard Group, Inc.
3,295,642
2.23%
41,925
0%
07/31/2018
Deka Investment GmbH
1,998,190
1.35%
1,235,129
0.1%
06/29/2018
BlackRock Asset Management Deutschland AG
1,789,819
1.21%
0
0.11%
09/07/2018
Oberweis Asset Management, Inc.
1,617,500
1.1%
1,043,800
1.72%
03/31/2018
Principal Global Investors LLC
1,582,697
1.07%
-49,861
0.03%
08/31/2018
BlackRock Fund Advisors
1,221,780
0.83%
715
0%
09/06/2018
Amundi Asset Management SA (Investment Management)
1,175,737
0.8%
0
0.05%
01/31/2018
| Address |
Manfred Eigen Campus
Hamburg Hamburg 22419
Germany
|
|
Employees
|
- |
| Website |
http://evotec.com |
| Updated |
07/08/2019 |
| Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. |
